Centrexion Therapeutics Corp - FORM S-1 - EX-23.1 - October 19, 2018

Attached files

file filename
EX-21.1 - EX-21.1 - Centrexion Therapeutics Corpd617454dex211.htm
EX-10.10 - EX-10.10 - Centrexion Therapeutics Corpd617454dex1010.htm
EX-10.9 - EX-10.9 - Centrexion Therapeutics Corpd617454dex109.htm
EX-10.8 - EX-10.8 - Centrexion Therapeutics Corpd617454dex108.htm
EX-10.7 - EX-10.7 - Centrexion Therapeutics Corpd617454dex107.htm
EX-10.6.2 - EX-10.6.2 - Centrexion Therapeutics Corpd617454dex1062.htm
EX-10.6.1 - EX-10.6.1 - Centrexion Therapeutics Corpd617454dex1061.htm
EX-10.5 - EX-10.5 - Centrexion Therapeutics Corpd617454dex105.htm
EX-10.1 - EX-10.1 - Centrexion Therapeutics Corpd617454dex101.htm
EX-4.8 - EX-4.8 - Centrexion Therapeutics Corpd617454dex48.htm
EX-4.7 - EX-4.7 - Centrexion Therapeutics Corpd617454dex47.htm
EX-4.6 - EX-4.6 - Centrexion Therapeutics Corpd617454dex46.htm
EX-4.5 - EX-4.5 - Centrexion Therapeutics Corpd617454dex45.htm
EX-4.4 - EX-4.4 - Centrexion Therapeutics Corpd617454dex44.htm
EX-4.3 - EX-4.3 - Centrexion Therapeutics Corpd617454dex43.htm
EX-4.1 - EX-4.1 - Centrexion Therapeutics Corpd617454dex41.htm
EX-3.2 - EX-3.2 - Centrexion Therapeutics Corpd617454dex32.htm
EX-3.1 - EX-3.1 - Centrexion Therapeutics Corpd617454dex31.htm
S-1 - S-1 - Centrexion Therapeutics Corpd617454ds1.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Centrexion Therapeutics Corporation:

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus. Our report dated September 10, 2018, contains an explanatory paragraph that states that the Company has incurred operating losses and negative cash flows from operations since inception, which raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of that uncertainty.

/s/ KMPG LLP

Cambridge, MA

October 19, 2018

Also read